[Manhattan Federal Courthouse, Foley Square — August 14, 2012, 11:22 AM]
She was waiting for a different courtroom.
I knew this because she was standing outside Room 412 with a messenger bag over one shoulder and a document folder in her hand, and the motion I had just finished was in 408, and people who stand outside 412 are waiting for 412. Maren Vance was waiting for her own errand.
She saw me come through the door, did a quick recalibration of whatever she had been planning to do with the next ten minutes, and fell in beside me down the corridor.
"I've been meaning to tell you." No preamble, no social entry. Her voice had the quality of someone picking up a conversation she had already been having internally. "The Meridian filing last month. That was a good read on the FDA approval window."
I kept walking. The Meridian matter was public record — filed with the court, available on PACER, nothing confidential. What was not public was the timing: I had filed the motion two weeks before the FDA's guidance came out, anticipating the guidance rather than responding to it. The move had been Library-supported — a straightforward tag chain on the FDA's informal comment process that had given me a reasonably specific window. To anyone watching from outside, it looked like a very specific read on a process most practitioners waited to see resolved before acting.
She had noticed.
"Most people filed after the guidance," she said. "You filed before. Either good source work or a very specific model."
Detection ran the sentence.
It was not a lie. It was also not bravado — the sentence lacked the particular quality of a person who is performing confidence they don't entirely feel. The certainty was load-bearing. It was the same quality I had read in her at the closing dinner, the same register: not inference, not analysis, not conclusion from publicly available data. Certainty-from-prior-knowledge, the same frequency I heard in my own sentences when I was saying something I knew from a source I couldn't name.
The rational conclusion: an activist fund with serious opposition-research capacity running a deep read on Klein Legal's regulatory practice. They monitored filing timestamps. They noticed preparation anomalies. It was unusual but it was not impossible.
I filed it under well-sourced operator.
"Good source work," I said.
She looked at me with the precise quality of someone who has just heard the answer they expected and has decided not to push on it. The look lasted about half a second.
"The Darby arrangement," she said, slightly differently. Transitioning to another register. "I give it two years at the outside. Maybe twenty-two months if the Hessington matter goes sideways."
My stride didn't break. The corridor was doing its midmorning thing — attorneys and clerks, two a-suit moving with the urgency of people who had been somewhere and needed to be somewhere else, the institutional background noise of a building that had been processing legal work for longer than most of the people in it had been alive.
"The Darby partnership is a significant merger," I said. "What makes you think twenty-two months."
She shrugged — not dismissively, the shrug of someone who has done the analysis and doesn't need to recite it out loud. "Partnership agreements with English managing partners and American legacy structures have a specific failure dynamic. Darby controls the board on paper. Jessica Pearson controls the floor. Those things resolve eventually. They resolve faster when the flagship case underperforms." She glanced at me. "The Hessington matter."
Detection: the Darby timeline sentence — not bravado. Certainty-from-prior-knowledge again.
She was right. She was right in the way that a person who has watched the show knows the end of the season — the Darby partnership was going to dissolve, approximately when she was predicting, for approximately the reason she was naming. In canon the timeline had been somewhere between eighteen and twenty-four months from the merger. The details she was providing — Jessica/Darby power dynamic, Hessington as the pressure point — were real and specific and not the kind of thing an activist fund's opposition research generated by watching public filings.
But Maren Vance ran an activist short-selling operation. She had, presumably, people inside major institutions who told her things. A fund with the right sources inside PD could have a specific model for the partnership's failure dynamics. It was unusual. It was not impossible.
She's a very good operator who has done very specific intelligence work on the Darby structure.
Three attorneys came around the corner ahead of us. I registered them before I had consciously decided to. The lead one — male, early thirties, PD associate by the bag and the specific haircut — was the one who had been at Vaughn's table in August, one of the flanking associates who had not spoken during the meeting but whose notepad had been open for the duration.
I did not change pace. I did not look away from the conversation. But I routed what I was about to say through the filter of he will remember this if he remembers anything.
Maren noticed my attention shift by approximately two degrees. She was good enough to notice that.
"Anyway." She switched registers again, light and complete, the way someone closes a window. "The Meridian timing — FDA advisory window, your specific prediction. If you're watching the informal comment process for the next six months, the biotech approvals are running faster than the public timeline suggests. There's a gap between the informal guidance and the formal announcement."
The PD associates passed. The one I recognized glanced at Maren, glanced at me, kept walking with the specific non-acknowledgment of someone who has filed a data point and will review it later.
I looked at Maren.
"The gap is how wide."
"Three weeks, maybe four. The informal comments are running clean on the oncology applications. Someone watching the pipeline closely would know that by October."
Three weeks. Four weeks. The Liang/Meridian Bio FDA regulatory matter had a filing deadline in November. If the informal comment process was running clean and the approval window was actually three weeks earlier than the formal timeline, Don needed to adjust the Liang strategy before October.
The Library, very quietly, ran a cross-reference on what Maren had just described. The purchased LP I had converted before the hearing — 2 LP, basic cross-reference capacity — returned a partial match: the FDA informal comment database had been running accelerated response timelines in the oncology applications for the last six weeks. The public announcement of any acceleration had not been made. The data was publicly available in theory and almost entirely unread in practice, buried in three-hundred-page comment files that nobody except a fund specifically watching regulatory timelines had read.
She had read them. Or someone she trusted had.
Good source work, I thought again. Very good source work.
"I'll look at it," I said.
"I know." She adjusted the messenger bag on her shoulder. Checked her watch — not actually checking the time, checking the time as a way of indicating she was about to go. "The 412 hearing is mine. Good luck with the motion outcome."
"How do you know I had a motion."
A small smile. Not coy. Just the smile of someone who has done their research and finds the question slightly endearing in its formality.
"You're Don Klein and it's a Tuesday morning in federal court," she said. "You had a motion."
She went back toward 412.
I stood in the corridor for approximately three seconds, running the conversation through Detection one more time with the specific attention I give replays when something has registered but I haven't fully processed it yet.
Darby dissolution: two years. Hessington pressure point. FDA biotech approval window. Filing before the guidance, noted and named.
The certainty-from-knowledge register had fired twice. It was a distinctive frequency and I knew it and it was the same frequency I ran in my own sentences, but it was also — conclusively, rationally — what a sharp operator with deep source work sounded like. Not impossible. Unusual. Very good.
I went downstairs and called Liang's office from the lobby.
The Meridian Bio regulatory strategy needed to move up the November filing by three weeks. If Maren was right about the FDA informal comment window, the adjusted timing would make the difference between a Q4 decision and a Q1 decision that would affect Liang's capital planning for the next six months. I told Liang's general counsel to accelerate the pre-filing review to October and got off the call before the end of the lobby atrium.
The Library logged it: #maren-vance-read-used. #debt-to-wildcard.
I had used her information. I had used it within forty minutes of receiving it, for a real client matter, with real consequences.
Whatever she was — sharp operator, deep source work, the specific certainty of someone who knew things for reasons she would not explain — she was now woven into the fabric of what Klein Legal was doing, one thread in a material that had not asked for it.
The PD associate from Vaughn's meeting had walked past thirty seconds after she said twenty-two months.
I went back to the office and did not tell anyone what had happened in the corridor.
✦ ━━━━━━━━━━━━━━━━━━━━━━━━ ✦
Read A LOT more chapters for free at unwrittenrealm.com
✦ ━━━━━━━━━━━━━━━━━━━━━━━━ ✦
TL;DR — Patreon has the chapters ahead.
Silver / $6 / 15 or more chap ahead
Gold / $9 / 20 or more chap ahead
Platinum / $15 / 25 or more chap ahead, no weekly wait
That's it. patreon.com/fanficwriter1
If reviews aren't your thing, no pressure — they do help though.